Avivagen Inc.

Ottawa, Canada

Avivagen Inc.

Ottawa, Canada
SEARCH FILTERS
Time filter
Source Type

News Article | May 8, 2017
Site: globenewswire.com

OTTAWA, Ontario, May 08, 2017 (GLOBE NEWSWIRE) -- Avivagen Inc. (TSXV:VIV), (OTC Pink:CHEXF) (Avivagen or the Corporation), a company with a proven and commercially-ready, patent-protected product intended to replace the antibiotics added to livestock feeds as growth promoters, announces that it intends to effect a 10 to 1 consolidation (the “Consolidation”) of its common shares. The date on which the Consolidation will take effect will be announced once the TSX Venture Exchange approval has been received. The Consolidation was approved by the Corporation’s shareholders at the annual general and special meeting of shareholders held on April 11, 2017. Kym Anthony, Chairman and Interim CEO stated, “We heard from a number of institutional investors and potential purchasers of our OxC-beta™ for Livestock product that we had the right operating company profile, but didn’t fit the appropriate capital markets profile in order for them to do business with us. As we consider international expansion and US capital markets strategies, we considered a consolidation factor of 10 – 20 old shares for each new share. Based on our view of our growth potential, we have unanimously selected the 10:1 ratio. We will provide another press release the day before the share consolidation will take effect.” Registered shareholders are requested to submit a completed letter of transmittal (a copy of which will be posted on the Corporation’s website and under the Corporation’s profile on www.sedar.com) together with their existing share certificates to Computershare Trust Company of Canada in exchange for post-consolidation share certificates. About Avivagen Avivagen Inc. is a public company traded on the TSXV under the symbol VIV and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada and Charlottetown, Prince Edward Island. For more information, visit www.avivagen.com. About OxC-beta™ Technology and OxC-beta™ Livestock Avivagen’s OxC-beta™ technology is derived from Avivagen discoveries about carotenoids, compounds that give certain fruits and vegetables their bright colors and is a non-antibiotic means of maintaining optimal health and growth. OxC-beta™ Livestock is a proprietary product shown to be effective and economic in replacing the antibiotics commonly added to livestock feeds.  OxC-beta™ Livestock is currently registered and available for sale in the Philippines, Taiwan and Thailand. Avivagen’s OxC-beta™ Livestock product is safe, effective and could fulfill the global mandate to remove all in-feed antibiotics as growth promoters. Numerous international livestock trials with poultry and swine using OxC-beta™ Livestock have proven that the product performs as well as, and, sometimes, in some aspects, better than in-feed antibiotics. Forward Looking Statements This news release includes certain forward-looking statements that are based upon the current expectations of management. Forward-looking statements involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions “could”, “expect”, “if”, “intend”, “may”, “will” and similar expressions or opinions of management. Avivagen faces risks and uncertainties in connection with its business, including, but not limited to, the following: Avivagen’s ability to continue as a going concern; whether the share consolidation will occur, if at all; whether the share consolidation, if implemented, will have the expected results as set out in the Corporation’s management information circular dated March 2, 2017; whether Avivagen will achieve any of the goals set out in this press release, if at all. Readers should also refer to the risk factors in Avivagen’s annual information form and other securities law filings from time to time. Accordingly, readers should not place undue or even any reliance on forward-looking statements.  Except as required by law, Avivagen assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Copyright © 2017 Avivagen Inc. OxC-beta™ is a trademark of Avivagen Inc.


News Article | May 8, 2017
Site: globenewswire.com

OTTAWA, Ontario, May 08, 2017 (GLOBE NEWSWIRE) -- Avivagen Inc. (TSXV:VIV), (OTC Pink:CHEXF) (Avivagen or the Corporation), a company with a proven and commercially-ready, patent-protected product intended to replace the antibiotics added to livestock feeds as growth promoters, announces that it intends to effect a 10 to 1 consolidation (the “Consolidation”) of its common shares. The date on which the Consolidation will take effect will be announced once the TSX Venture Exchange approval has been received. The Consolidation was approved by the Corporation’s shareholders at the annual general and special meeting of shareholders held on April 11, 2017. Kym Anthony, Chairman and Interim CEO stated, “We heard from a number of institutional investors and potential purchasers of our OxC-beta™ for Livestock product that we had the right operating company profile, but didn’t fit the appropriate capital markets profile in order for them to do business with us. As we consider international expansion and US capital markets strategies, we considered a consolidation factor of 10 – 20 old shares for each new share. Based on our view of our growth potential, we have unanimously selected the 10:1 ratio. We will provide another press release the day before the share consolidation will take effect.” Registered shareholders are requested to submit a completed letter of transmittal (a copy of which will be posted on the Corporation’s website and under the Corporation’s profile on www.sedar.com) together with their existing share certificates to Computershare Trust Company of Canada in exchange for post-consolidation share certificates. About Avivagen Avivagen Inc. is a public company traded on the TSXV under the symbol VIV and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada and Charlottetown, Prince Edward Island. For more information, visit www.avivagen.com. About OxC-beta™ Technology and OxC-beta™ Livestock Avivagen’s OxC-beta™ technology is derived from Avivagen discoveries about carotenoids, compounds that give certain fruits and vegetables their bright colors and is a non-antibiotic means of maintaining optimal health and growth. OxC-beta™ Livestock is a proprietary product shown to be effective and economic in replacing the antibiotics commonly added to livestock feeds.  OxC-beta™ Livestock is currently registered and available for sale in the Philippines, Taiwan and Thailand. Avivagen’s OxC-beta™ Livestock product is safe, effective and could fulfill the global mandate to remove all in-feed antibiotics as growth promoters. Numerous international livestock trials with poultry and swine using OxC-beta™ Livestock have proven that the product performs as well as, and, sometimes, in some aspects, better than in-feed antibiotics. Forward Looking Statements This news release includes certain forward-looking statements that are based upon the current expectations of management. Forward-looking statements involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions “could”, “expect”, “if”, “intend”, “may”, “will” and similar expressions or opinions of management. Avivagen faces risks and uncertainties in connection with its business, including, but not limited to, the following: Avivagen’s ability to continue as a going concern; whether the share consolidation will occur, if at all; whether the share consolidation, if implemented, will have the expected results as set out in the Corporation’s management information circular dated March 2, 2017; whether Avivagen will achieve any of the goals set out in this press release, if at all. Readers should also refer to the risk factors in Avivagen’s annual information form and other securities law filings from time to time. Accordingly, readers should not place undue or even any reliance on forward-looking statements.  Except as required by law, Avivagen assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Copyright © 2017 Avivagen Inc. OxC-beta™ is a trademark of Avivagen Inc.


News Article | May 8, 2017
Site: globenewswire.com

OTTAWA, Ontario, May 08, 2017 (GLOBE NEWSWIRE) -- Avivagen Inc. (TSXV:VIV), (OTC Pink:CHEXF) (Avivagen or the Corporation), a company with a proven and commercially-ready, patent-protected product intended to replace the antibiotics added to livestock feeds as growth promoters, announces that it intends to effect a 10 to 1 consolidation (the “Consolidation”) of its common shares. The date on which the Consolidation will take effect will be announced once the TSX Venture Exchange approval has been received. The Consolidation was approved by the Corporation’s shareholders at the annual general and special meeting of shareholders held on April 11, 2017. Kym Anthony, Chairman and Interim CEO stated, “We heard from a number of institutional investors and potential purchasers of our OxC-beta™ for Livestock product that we had the right operating company profile, but didn’t fit the appropriate capital markets profile in order for them to do business with us. As we consider international expansion and US capital markets strategies, we considered a consolidation factor of 10 – 20 old shares for each new share. Based on our view of our growth potential, we have unanimously selected the 10:1 ratio. We will provide another press release the day before the share consolidation will take effect.” Registered shareholders are requested to submit a completed letter of transmittal (a copy of which will be posted on the Corporation’s website and under the Corporation’s profile on www.sedar.com) together with their existing share certificates to Computershare Trust Company of Canada in exchange for post-consolidation share certificates. About Avivagen Avivagen Inc. is a public company traded on the TSXV under the symbol VIV and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada and Charlottetown, Prince Edward Island. For more information, visit www.avivagen.com. About OxC-beta™ Technology and OxC-beta™ Livestock Avivagen’s OxC-beta™ technology is derived from Avivagen discoveries about carotenoids, compounds that give certain fruits and vegetables their bright colors and is a non-antibiotic means of maintaining optimal health and growth. OxC-beta™ Livestock is a proprietary product shown to be effective and economic in replacing the antibiotics commonly added to livestock feeds.  OxC-beta™ Livestock is currently registered and available for sale in the Philippines, Taiwan and Thailand. Avivagen’s OxC-beta™ Livestock product is safe, effective and could fulfill the global mandate to remove all in-feed antibiotics as growth promoters. Numerous international livestock trials with poultry and swine using OxC-beta™ Livestock have proven that the product performs as well as, and, sometimes, in some aspects, better than in-feed antibiotics. Forward Looking Statements This news release includes certain forward-looking statements that are based upon the current expectations of management. Forward-looking statements involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions “could”, “expect”, “if”, “intend”, “may”, “will” and similar expressions or opinions of management. Avivagen faces risks and uncertainties in connection with its business, including, but not limited to, the following: Avivagen’s ability to continue as a going concern; whether the share consolidation will occur, if at all; whether the share consolidation, if implemented, will have the expected results as set out in the Corporation’s management information circular dated March 2, 2017; whether Avivagen will achieve any of the goals set out in this press release, if at all. Readers should also refer to the risk factors in Avivagen’s annual information form and other securities law filings from time to time. Accordingly, readers should not place undue or even any reliance on forward-looking statements.  Except as required by law, Avivagen assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Copyright © 2017 Avivagen Inc. OxC-beta™ is a trademark of Avivagen Inc.


News Article | May 8, 2017
Site: globenewswire.com

OTTAWA, Ontario, May 08, 2017 (GLOBE NEWSWIRE) -- Avivagen Inc. (TSXV:VIV), (OTC Pink:CHEXF) (Avivagen or the Corporation), a company with a proven and commercially-ready, patent-protected product intended to replace the antibiotics added to livestock feeds as growth promoters, announces that it intends to effect a 10 to 1 consolidation (the “Consolidation”) of its common shares. The date on which the Consolidation will take effect will be announced once the TSX Venture Exchange approval has been received. The Consolidation was approved by the Corporation’s shareholders at the annual general and special meeting of shareholders held on April 11, 2017. Kym Anthony, Chairman and Interim CEO stated, “We heard from a number of institutional investors and potential purchasers of our OxC-beta™ for Livestock product that we had the right operating company profile, but didn’t fit the appropriate capital markets profile in order for them to do business with us. As we consider international expansion and US capital markets strategies, we considered a consolidation factor of 10 – 20 old shares for each new share. Based on our view of our growth potential, we have unanimously selected the 10:1 ratio. We will provide another press release the day before the share consolidation will take effect.” Registered shareholders are requested to submit a completed letter of transmittal (a copy of which will be posted on the Corporation’s website and under the Corporation’s profile on www.sedar.com) together with their existing share certificates to Computershare Trust Company of Canada in exchange for post-consolidation share certificates. About Avivagen Avivagen Inc. is a public company traded on the TSXV under the symbol VIV and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada and Charlottetown, Prince Edward Island. For more information, visit www.avivagen.com. About OxC-beta™ Technology and OxC-beta™ Livestock Avivagen’s OxC-beta™ technology is derived from Avivagen discoveries about carotenoids, compounds that give certain fruits and vegetables their bright colors and is a non-antibiotic means of maintaining optimal health and growth. OxC-beta™ Livestock is a proprietary product shown to be effective and economic in replacing the antibiotics commonly added to livestock feeds.  OxC-beta™ Livestock is currently registered and available for sale in the Philippines, Taiwan and Thailand. Avivagen’s OxC-beta™ Livestock product is safe, effective and could fulfill the global mandate to remove all in-feed antibiotics as growth promoters. Numerous international livestock trials with poultry and swine using OxC-beta™ Livestock have proven that the product performs as well as, and, sometimes, in some aspects, better than in-feed antibiotics. Forward Looking Statements This news release includes certain forward-looking statements that are based upon the current expectations of management. Forward-looking statements involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions “could”, “expect”, “if”, “intend”, “may”, “will” and similar expressions or opinions of management. Avivagen faces risks and uncertainties in connection with its business, including, but not limited to, the following: Avivagen’s ability to continue as a going concern; whether the share consolidation will occur, if at all; whether the share consolidation, if implemented, will have the expected results as set out in the Corporation’s management information circular dated March 2, 2017; whether Avivagen will achieve any of the goals set out in this press release, if at all. Readers should also refer to the risk factors in Avivagen’s annual information form and other securities law filings from time to time. Accordingly, readers should not place undue or even any reliance on forward-looking statements.  Except as required by law, Avivagen assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Copyright © 2017 Avivagen Inc. OxC-beta™ is a trademark of Avivagen Inc.


News Article | May 12, 2017
Site: globenewswire.com

OTTAWA, Ontario, May 12, 2017 (GLOBE NEWSWIRE) -- Avivagen Inc. (TSXV:VIV) (OTC Pink:CHEXF) (Avivagen or the Corporation), a Corporation with a proven and commercially-ready, patent-protected product intended to replace the antibiotics added to livestock feeds as growth promoters, announces the hiring of a regulatory consulting firm to work with the Corporation to analyze and seek regulatory approvals of Avivagen’s OxC-beta™ for Livestock in the United States. Avivagen has already secured approvals in several Asian markets and will be seeking to confirm the regulatory pathway for approvals in the U.S., Europe, South America and other important markets. Avivagen believes that obtaining  regulatory approval in additional jurisdictions could  increase the market access of OxC-beta™ for Livestock, as well as assist in securing potential licensing and distribution partners in those markets. Avivagen has engaged BioPharmaPotentials, a consulting firm that works with select inventors, entrepreneurs, investigators and investors to maximize the full potential for new and current chemical and biologic entities within the field of animal health. BioPharmaPotentials’ founder and CEO, Dr. Edward Robb, DVM, MS, DACVN, has held leadership research and development positions at Boehringer-Ingelheim Vetmedica, Pfizer Animal Health, Pharmacia and Upjohn Animal Health, Parnell, CEVA, Embrex and American Cyanamid. About Avivagen Avivagen Inc. is a public Corporation traded on the TSXV under the symbol VIV and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada and Charlottetown, Prince Edward Island. For more information, visit www.avivagen.com. About OxC-beta™ Technology and OxC-beta™ Livestock Avivagen’s OxC-beta™ technology is derived from Avivagen discoveries about carotenoids, compounds that give certain fruits and vegetables their bright colors and is a non-antibiotic means of maintaining optimal health and growth. OxC-beta™ Livestock is a proprietary product shown to be effective and economic in replacing the antibiotics commonly added to livestock feeds.  OxC-beta™ Livestock is currently registered and available for sale in the Philippines, Taiwan and Thailand. Avivagen’s OxC-beta™ Livestock product is safe, effective and could fulfill the global mandate to remove all in-feed antibiotics as growth promoters. Numerous international livestock trials with poultry and swine using OxC-beta™ Livestock have proven that the product performs as well as, and, sometimes, in some aspects, better than in-feed antibiotics. Forward Looking Statements This news release includes certain forward-looking statements that are based upon the current expectations of management. Forward-looking statements involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions “aim”, “anticipate”, “appear”, “believe”, “consider”, “could”, “estimate”, “expect”, “if”, “intend”, “goal”, ”helps”, “hope”, “likely”, “may”, “plan”, “possibly”, “potentially”, “pursue”, “seem”, “should”, “whether”, “will”, “would” and similar expressions or opinions of management. Statements relating to Avivagen’s planned activities with its regulatory consulting firm, its plans to seek regulatory approval in additional jurisdictions and the potential effects of the receipt of any such approvals, are all forward-looking statements. Avivagen faces risks and uncertainties in connection with its business, including, but not limited to, risks relating to the following: Avivagen’s ability to continue as a going concern; whether the Corporation can expand its global regulatory advisor network in order to gain market approval of OxC-beta™; whether the Corporation can obtain market approval in additional geographies, if at all; whether it will be able to replace the antibiotics added to livestock feeds as growth promoters, whether it will confirm and expedite potential regulatory approvals of Avivagen’s OxC-beta™ for Livestock in major markets around the world, whether it will seek and be able to confirm the regulatory pathway for approvals in the U.S., Europe, South America and all other important markets, whether it will confirm, define and potentially expedite regulatory pathways for approval, whether any such approvals will be applied for or received in a timely manner or at all,  whether it will increase the market access of OxC-beta™ for Livestock, whether it will secure potential licensing and distribution partners in those markets and whether it can assure the full potential for the Corporation.   Avivagen may decide not to seek regulatory approval for its products in additional jurisdictions, regulatory approvals for Avivagen’s products may not be available in one or more additional jurisdictions in a timely or cost effective manner, if at all, and, if received, such approvals may not have the anticipated positive effects on the Corporation’s business and prospects. Readers should also refer to the risk factors in Avivagen’s annual information form and other securities law filings from time to time. Accordingly, readers should not place undue or even any reliance on forward-looking statements.  Except as required by law, Avivagen assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


News Article | May 12, 2017
Site: globenewswire.com

OTTAWA, Ontario, May 12, 2017 (GLOBE NEWSWIRE) -- Avivagen Inc. (TSXV:VIV) (OTC Pink:CHEXF) (Avivagen or the Corporation), a Corporation with a proven and commercially-ready, patent-protected product intended to replace the antibiotics added to livestock feeds as growth promoters, announces the hiring of a regulatory consulting firm to work with the Corporation to analyze and seek regulatory approvals of Avivagen’s OxC-beta™ for Livestock in the United States. Avivagen has already secured approvals in several Asian markets and will be seeking to confirm the regulatory pathway for approvals in the U.S., Europe, South America and other important markets. Avivagen believes that obtaining  regulatory approval in additional jurisdictions could  increase the market access of OxC-beta™ for Livestock, as well as assist in securing potential licensing and distribution partners in those markets. Avivagen has engaged BioPharmaPotentials, a consulting firm that works with select inventors, entrepreneurs, investigators and investors to maximize the full potential for new and current chemical and biologic entities within the field of animal health. BioPharmaPotentials’ founder and CEO, Dr. Edward Robb, DVM, MS, DACVN, has held leadership research and development positions at Boehringer-Ingelheim Vetmedica, Pfizer Animal Health, Pharmacia and Upjohn Animal Health, Parnell, CEVA, Embrex and American Cyanamid. About Avivagen Avivagen Inc. is a public Corporation traded on the TSXV under the symbol VIV and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada and Charlottetown, Prince Edward Island. For more information, visit www.avivagen.com. About OxC-beta™ Technology and OxC-beta™ Livestock Avivagen’s OxC-beta™ technology is derived from Avivagen discoveries about carotenoids, compounds that give certain fruits and vegetables their bright colors and is a non-antibiotic means of maintaining optimal health and growth. OxC-beta™ Livestock is a proprietary product shown to be effective and economic in replacing the antibiotics commonly added to livestock feeds.  OxC-beta™ Livestock is currently registered and available for sale in the Philippines, Taiwan and Thailand. Avivagen’s OxC-beta™ Livestock product is safe, effective and could fulfill the global mandate to remove all in-feed antibiotics as growth promoters. Numerous international livestock trials with poultry and swine using OxC-beta™ Livestock have proven that the product performs as well as, and, sometimes, in some aspects, better than in-feed antibiotics. Forward Looking Statements This news release includes certain forward-looking statements that are based upon the current expectations of management. Forward-looking statements involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions “aim”, “anticipate”, “appear”, “believe”, “consider”, “could”, “estimate”, “expect”, “if”, “intend”, “goal”, ”helps”, “hope”, “likely”, “may”, “plan”, “possibly”, “potentially”, “pursue”, “seem”, “should”, “whether”, “will”, “would” and similar expressions or opinions of management. Statements relating to Avivagen’s planned activities with its regulatory consulting firm, its plans to seek regulatory approval in additional jurisdictions and the potential effects of the receipt of any such approvals, are all forward-looking statements. Avivagen faces risks and uncertainties in connection with its business, including, but not limited to, risks relating to the following: Avivagen’s ability to continue as a going concern; whether the Corporation can expand its global regulatory advisor network in order to gain market approval of OxC-beta™; whether the Corporation can obtain market approval in additional geographies, if at all; whether it will be able to replace the antibiotics added to livestock feeds as growth promoters, whether it will confirm and expedite potential regulatory approvals of Avivagen’s OxC-beta™ for Livestock in major markets around the world, whether it will seek and be able to confirm the regulatory pathway for approvals in the U.S., Europe, South America and all other important markets, whether it will confirm, define and potentially expedite regulatory pathways for approval, whether any such approvals will be applied for or received in a timely manner or at all,  whether it will increase the market access of OxC-beta™ for Livestock, whether it will secure potential licensing and distribution partners in those markets and whether it can assure the full potential for the Corporation.   Avivagen may decide not to seek regulatory approval for its products in additional jurisdictions, regulatory approvals for Avivagen’s products may not be available in one or more additional jurisdictions in a timely or cost effective manner, if at all, and, if received, such approvals may not have the anticipated positive effects on the Corporation’s business and prospects. Readers should also refer to the risk factors in Avivagen’s annual information form and other securities law filings from time to time. Accordingly, readers should not place undue or even any reliance on forward-looking statements.  Except as required by law, Avivagen assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


News Article | May 12, 2017
Site: globenewswire.com

OTTAWA, Ontario, May 12, 2017 (GLOBE NEWSWIRE) -- Avivagen Inc. (TSXV:VIV) (OTC Pink:CHEXF) (Avivagen or the Corporation), a Corporation with a proven and commercially-ready, patent-protected product intended to replace the antibiotics added to livestock feeds as growth promoters, announces the hiring of a regulatory consulting firm to work with the Corporation to analyze and seek regulatory approvals of Avivagen’s OxC-beta™ for Livestock in the United States. Avivagen has already secured approvals in several Asian markets and will be seeking to confirm the regulatory pathway for approvals in the U.S., Europe, South America and other important markets. Avivagen believes that obtaining  regulatory approval in additional jurisdictions could  increase the market access of OxC-beta™ for Livestock, as well as assist in securing potential licensing and distribution partners in those markets. Avivagen has engaged BioPharmaPotentials, a consulting firm that works with select inventors, entrepreneurs, investigators and investors to maximize the full potential for new and current chemical and biologic entities within the field of animal health. BioPharmaPotentials’ founder and CEO, Dr. Edward Robb, DVM, MS, DACVN, has held leadership research and development positions at Boehringer-Ingelheim Vetmedica, Pfizer Animal Health, Pharmacia and Upjohn Animal Health, Parnell, CEVA, Embrex and American Cyanamid. About Avivagen Avivagen Inc. is a public Corporation traded on the TSXV under the symbol VIV and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada and Charlottetown, Prince Edward Island. For more information, visit www.avivagen.com. About OxC-beta™ Technology and OxC-beta™ Livestock Avivagen’s OxC-beta™ technology is derived from Avivagen discoveries about carotenoids, compounds that give certain fruits and vegetables their bright colors and is a non-antibiotic means of maintaining optimal health and growth. OxC-beta™ Livestock is a proprietary product shown to be effective and economic in replacing the antibiotics commonly added to livestock feeds.  OxC-beta™ Livestock is currently registered and available for sale in the Philippines, Taiwan and Thailand. Avivagen’s OxC-beta™ Livestock product is safe, effective and could fulfill the global mandate to remove all in-feed antibiotics as growth promoters. Numerous international livestock trials with poultry and swine using OxC-beta™ Livestock have proven that the product performs as well as, and, sometimes, in some aspects, better than in-feed antibiotics. Forward Looking Statements This news release includes certain forward-looking statements that are based upon the current expectations of management. Forward-looking statements involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions “aim”, “anticipate”, “appear”, “believe”, “consider”, “could”, “estimate”, “expect”, “if”, “intend”, “goal”, ”helps”, “hope”, “likely”, “may”, “plan”, “possibly”, “potentially”, “pursue”, “seem”, “should”, “whether”, “will”, “would” and similar expressions or opinions of management. Statements relating to Avivagen’s planned activities with its regulatory consulting firm, its plans to seek regulatory approval in additional jurisdictions and the potential effects of the receipt of any such approvals, are all forward-looking statements. Avivagen faces risks and uncertainties in connection with its business, including, but not limited to, risks relating to the following: Avivagen’s ability to continue as a going concern; whether the Corporation can expand its global regulatory advisor network in order to gain market approval of OxC-beta™; whether the Corporation can obtain market approval in additional geographies, if at all; whether it will be able to replace the antibiotics added to livestock feeds as growth promoters, whether it will confirm and expedite potential regulatory approvals of Avivagen’s OxC-beta™ for Livestock in major markets around the world, whether it will seek and be able to confirm the regulatory pathway for approvals in the U.S., Europe, South America and all other important markets, whether it will confirm, define and potentially expedite regulatory pathways for approval, whether any such approvals will be applied for or received in a timely manner or at all,  whether it will increase the market access of OxC-beta™ for Livestock, whether it will secure potential licensing and distribution partners in those markets and whether it can assure the full potential for the Corporation.   Avivagen may decide not to seek regulatory approval for its products in additional jurisdictions, regulatory approvals for Avivagen’s products may not be available in one or more additional jurisdictions in a timely or cost effective manner, if at all, and, if received, such approvals may not have the anticipated positive effects on the Corporation’s business and prospects. Readers should also refer to the risk factors in Avivagen’s annual information form and other securities law filings from time to time. Accordingly, readers should not place undue or even any reliance on forward-looking statements.  Except as required by law, Avivagen assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


News Article | May 12, 2017
Site: globenewswire.com

OTTAWA, Ontario, May 12, 2017 (GLOBE NEWSWIRE) -- Avivagen Inc. (TSXV:VIV) (OTC Pink:CHEXF) (Avivagen or the Corporation), a Corporation with a proven and commercially-ready, patent-protected product intended to replace the antibiotics added to livestock feeds as growth promoters, announces the hiring of a regulatory consulting firm to work with the Corporation to analyze and seek regulatory approvals of Avivagen’s OxC-beta™ for Livestock in the United States. Avivagen has already secured approvals in several Asian markets and will be seeking to confirm the regulatory pathway for approvals in the U.S., Europe, South America and other important markets. Avivagen believes that obtaining  regulatory approval in additional jurisdictions could  increase the market access of OxC-beta™ for Livestock, as well as assist in securing potential licensing and distribution partners in those markets. Avivagen has engaged BioPharmaPotentials, a consulting firm that works with select inventors, entrepreneurs, investigators and investors to maximize the full potential for new and current chemical and biologic entities within the field of animal health. BioPharmaPotentials’ founder and CEO, Dr. Edward Robb, DVM, MS, DACVN, has held leadership research and development positions at Boehringer-Ingelheim Vetmedica, Pfizer Animal Health, Pharmacia and Upjohn Animal Health, Parnell, CEVA, Embrex and American Cyanamid. About Avivagen Avivagen Inc. is a public Corporation traded on the TSXV under the symbol VIV and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada and Charlottetown, Prince Edward Island. For more information, visit www.avivagen.com. About OxC-beta™ Technology and OxC-beta™ Livestock Avivagen’s OxC-beta™ technology is derived from Avivagen discoveries about carotenoids, compounds that give certain fruits and vegetables their bright colors and is a non-antibiotic means of maintaining optimal health and growth. OxC-beta™ Livestock is a proprietary product shown to be effective and economic in replacing the antibiotics commonly added to livestock feeds.  OxC-beta™ Livestock is currently registered and available for sale in the Philippines, Taiwan and Thailand. Avivagen’s OxC-beta™ Livestock product is safe, effective and could fulfill the global mandate to remove all in-feed antibiotics as growth promoters. Numerous international livestock trials with poultry and swine using OxC-beta™ Livestock have proven that the product performs as well as, and, sometimes, in some aspects, better than in-feed antibiotics. Forward Looking Statements This news release includes certain forward-looking statements that are based upon the current expectations of management. Forward-looking statements involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions “aim”, “anticipate”, “appear”, “believe”, “consider”, “could”, “estimate”, “expect”, “if”, “intend”, “goal”, ”helps”, “hope”, “likely”, “may”, “plan”, “possibly”, “potentially”, “pursue”, “seem”, “should”, “whether”, “will”, “would” and similar expressions or opinions of management. Statements relating to Avivagen’s planned activities with its regulatory consulting firm, its plans to seek regulatory approval in additional jurisdictions and the potential effects of the receipt of any such approvals, are all forward-looking statements. Avivagen faces risks and uncertainties in connection with its business, including, but not limited to, risks relating to the following: Avivagen’s ability to continue as a going concern; whether the Corporation can expand its global regulatory advisor network in order to gain market approval of OxC-beta™; whether the Corporation can obtain market approval in additional geographies, if at all; whether it will be able to replace the antibiotics added to livestock feeds as growth promoters, whether it will confirm and expedite potential regulatory approvals of Avivagen’s OxC-beta™ for Livestock in major markets around the world, whether it will seek and be able to confirm the regulatory pathway for approvals in the U.S., Europe, South America and all other important markets, whether it will confirm, define and potentially expedite regulatory pathways for approval, whether any such approvals will be applied for or received in a timely manner or at all,  whether it will increase the market access of OxC-beta™ for Livestock, whether it will secure potential licensing and distribution partners in those markets and whether it can assure the full potential for the Corporation.   Avivagen may decide not to seek regulatory approval for its products in additional jurisdictions, regulatory approvals for Avivagen’s products may not be available in one or more additional jurisdictions in a timely or cost effective manner, if at all, and, if received, such approvals may not have the anticipated positive effects on the Corporation’s business and prospects. Readers should also refer to the risk factors in Avivagen’s annual information form and other securities law filings from time to time. Accordingly, readers should not place undue or even any reliance on forward-looking statements.  Except as required by law, Avivagen assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


LONDON, UK / ACCESSWIRE / February 16, 2017 / Active Wall St. announces the list of stocks for today's research reports. Pre-market the Active Wall St. team provides the technical coverage impacting selected stocks trading on the Toronto Exchange and belonging under the Drug Manufacturers industry. Companies recently under review include Nuvo Pharmaceuticals, Acerus Pharmaceuticals, and Avivagen. Get all of our free research reports by signing up at: On Wednesday, February 15, 2017, the Toronto Exchange Composite Index was up 0.37%, finishing the day at 15,844.95. The TSX Venture Composite Index, on the other hand, closed at 838.14, up 0.34%. Additionally, the Healthcare index was up by 3.22%, ending the session at 77.28. Active Wall St. has initiated research reports on the following equities: Nuvo Pharmaceuticals Inc. (TSX: NRI), Acerus Pharmaceuticals Corporation (TSX: ASP), and Avivagen Inc. (TSXV: VIV). Register with us now for your free membership and research reports at: On Wednesday, shares in Mississauga, Canada-based Nuvo Pharmaceuticals Inc. recorded a trading volume of 26,248 shares, which was higher than their three months' average volume of 11,539 shares. The stock ended the day 1.60% lower at $5.54. Nuvo Pharma's stock has advanced 1.47% in the last one month and 12.80% in the previous one year. The Company's shares are trading above its 50-day moving average. The stock's 200-day moving average of $6.31 is above its 50-day moving average of $5.51. Shares of the Company, which operates as a life sciences company, are trading at PE ratio of 1,108.00. See our research report on NRI.TO at: Mississauga, Canada headquartered Acerus Pharmaceuticals Corp.'s stock finished Wednesday's session flat at $0.13 with a total volume of 462,169 shares traded. Over the last one month and the previous three months, Acerus Pharma's shares have rallied 6,971.43% and 7,515.38%, respectively. Furthermore, the stock has rallied 2,202.33% in the past one year. The Company's shares are trading below its 50-day and 200-day moving averages. Acerus Pharma' 50-day moving average of $1.29 is above its 200-day moving average of $0.44. Shares of the Company, which focuses on developing, manufacturing, marketing, and distributing pharmaceutical products for male hypogonadism, women's hormone replacement therapy, and female sexual dysfunction in Canada, are trading at a PE ratio of 9.29. The complimentary research report on ASP.TO at: Ottawa, Canada headquartered Avivagen Inc.'s stock closed the day 4.55% lower at $0.10. The stock recorded a trading volume of 510,000 shares, which was above its three months' average volume of 372,163 shares. Shares of the company, which develops and commercializes various products to replace antibiotics in livestock feeds to optimize the health and growth of the animals by supporting the animal's own health defenses, are trading below their 50-day and 200-day moving averages. Moreover, the stock's 200-day moving average of $0.15 is greater than its 50-day moving average of $0.12. Get free access to your research report on VIV.V at: Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. AWS has not been compensated; directly or indirectly; for producing or publishing this document. The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way. AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/. For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


Patent
Avivagen Inc. | Date: 2016-05-13

The invention features compositions, methods, and kits for the administration of an oxidatively transformed carotenoid, or a fractionated component thereof, for use in aquaculture.

Loading Avivagen Inc. collaborators
Loading Avivagen Inc. collaborators